Comparative Pharmacology
Head-to-head clinical analysis: KRINTAFEL versus PRIMAQUINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KRINTAFEL versus PRIMAQUINE.
KRINTAFEL vs PRIMAQUINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KRINTAFEL (tafenoquine) is an 8-aminoquinoline antimalarial that inhibits parasite growth by interfering with the electron transport chain in the mitochondria of Plasmodium species. It is active against both the erythrocytic and exoerythrocytic stages, including hypnozoites of P. vivax.
Antimalarial agent that eliminates exoerythrocytic forms (hypnozoites) of Plasmodium vivax and P. ovale; also active against gametocytes. Mechanism involves generation of reactive oxygen species via redox cycling, disrupting parasite mitochondrial function.
Adults: 200 mg orally as a single dose.
15 mg (base) orally once daily for 14 days for radical cure of P. vivax and P. ovale; 30 mg (base) orally once daily for 7 days for terminal prophylaxis.
None Documented
None Documented
Clinical Note
moderatePrimaquine + Norfloxacin
"Primaquine may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderatePrimaquine + Haloperidol
"Primaquine may increase the QTc-prolonging activities of Haloperidol."
Clinical Note
moderatePrimaquine + Ibandronate
"Primaquine may increase the QTc-prolonging activities of Ibandronate."
Clinical Note
moderatePrimaquine + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Primaquine."
Terminal elimination half-life is approximately 5-7 days in healthy subjects. Due to accumulation, steady state is achieved after 4-5 weeks of weekly dosing. In patients with renal impairment, half-life may be prolonged.
Terminal elimination half-life of approximately 4-7 hours; in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, half-life may be prolonged due to accumulation in erythrocytes
Primarily renal; approximately 70-80% of administered dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Fecal excretion accounts for less than 5%.
Primarily renal (60-65% as unchanged drug and metabolites); small amounts in feces (<5%)
Category C
Category D/X
Antimalarial
Antimalarial